An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease

The FDA decision to grant accelerated approval to aducanumab for Alzheimer’s disease fits squarely in the accelerated approval pathway, which was created to allow patients with a serious or life-threatening disease earlier access to a potentially important treatment.

留言 (0)

沒有登入
gif